Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | STS | P08842 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | GHSR | Q92847 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5318595 | 0.86 | NPC1 (0.37) | MAPTMAPK1ALDH1A1IDO1 | |
| SCHEMBL4860975 | 0.84 | MAPK1 (0.34) | STSMAPTMAPK1KDM4EPKM | |
| SCHEMBL4862831 | 0.81 | TDP1 (0.34) | MAPK1NPSR1KDM4EPKMNAMPT | |
| SCHEMBL22030527 | 0.73 | PARP1 (0.40) | MEN1KMT2ASTSMAPTPARP1 | |
| SCHEMBL16187271 | 0.69 | GPR119 (0.42) | KMT2ASTSPARP1JAK2JAK1 | |
| SCHEMBL994681 | 0.69 | USP30 (0.60) | STSPARP1JAK2JAK1GPR119 | |
| SCHEMBL18655393 | 0.69 | USP30 (0.60) | STSPARP1JAK2JAK1GPR119 | |
| SCHEMBL994668 | 0.69 | STS (0.43) | MEN1KMT2ASTSJAK2JAK1 | |
| SCHEMBL4856100 | 0.68 | MAPK1 (0.38) | MEN1KMT2ASTSJAK2JAK1 | |
| SCHEMBL14746164 | 0.68 | KLK7 (0.43) | MEN1KMT2ASTSPARP1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365071-B2 | Heterocyclic compounds, preparation process and intermediates, and use as medicaments, in particular as β-lactamase inhibitors and antibacterials | AVENTIS PHARMA S.A. (FR) | 2008-04-29 | — | — | US | disclosed |
| US-7365071-B2 | Heterocyclic compounds, preparation process and intermediates, and use as medicaments, in particular as β-lactamase inhibitors and antibacterials | AVENTIS PHARMA S.A. (FR) | 2008-04-29 | — | — | US | disclosed |
| US-7365071-B2 | Heterocyclic compounds, preparation process and intermediates, and use as medicaments, in particular as β-lactamase inhibitors and antibacterials | AVENTIS PHARMA S.A. (FR) | 2008-04-29 | — | — | US | disclosed |
| US-20070191312-A1 | NOVEL HETEROCYCLIC COMPOUNDS, PREPARATION PROCESS AND INTERMEDIATES, AND USE AS MEDICAMENTS, IN PARTICULAR AS BETA-LACTAMASE INHIBITORS AND ANTIBACTERIALS | MUSICKI BRANISLAV | 2007-08-16 | — | — | US | disclosed |
| US-20070191312-A1 | NOVEL HETEROCYCLIC COMPOUNDS, PREPARATION PROCESS AND INTERMEDIATES, AND USE AS MEDICAMENTS, IN PARTICULAR AS BETA-LACTAMASE INHIBITORS AND ANTIBACTERIALS | MUSICKI BRANISLAV | 2007-08-16 | — | — | US | disclosed |
| US-20040097490-A1 | Novel heterocyclic compounds, preparation process and intermediates, and use as medicaments, in particular as B-lactamase inhibitors and antibacterials | AVENTIS PHARMA S.A. (FR) | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097490-A1 | Novel heterocyclic compounds, preparation process and intermediates, and use as medicaments, in particular as B-lactamase inhibitors and antibacterials | GAA, BBOX1, BPGM | MEN1 610/4885KMT2A 2560/4885STS 74/4885 |
| US-20070191312-A1 | NOVEL HETEROCYCLIC COMPOUNDS, PREPARATION PROCESS AND INTERMEDIATES, AND USE AS MEDICAMENTS, IN PARTICULAR AS BETA-LACTAMASE INHIBITORS AND ANTIBACTERIALS | GAA, PEPD, MGAM | MEN1 795/4885KMT2A 2634/4885STS 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.